Verified E.R.A.
New Operating Model Project
New Operating Model Project 🇯🇵 JA  新オペレーティングモデルPJ
🇩🇪 DE  Neues Betriebsmodell-Projekt
🇬🇧 FR  Projet de nouveau modèle opérationnel
🇪🇸 ES  Proyecto de nuevo modelo operativo
🇨🇳 ZH  新运营模式项目
🇰🇷 KO  새 운영 모녂 프로잨트
🇦🇪 AR  مشروع نموذج التشغيل الجديد
🇮🇹 IT  Nuovo progetto di modello operativo
🇧🇷 PT-BR  Projeto de novo modelo operacional
How — Patient Record

A New Operating Model for Rare Disease

Not a reimagination of the existing process. A new one, built from the patient backward, eliminating every step that does not serve speed, safety, or efficacy. The data has to travel with the patient — not the health system, not the insurer, not the institution. The patient.

November 2026

There is a category of disease where the development timeline is not just a failure of science. It is a failure of architecture. The operating model of drug development was not designed for a disease affecting 500 people globally. It was designed for blockbusters, for populations of hundreds of thousands, for review processes built around the assumption of time.

Rare disease patients do not have time. The five diseases in this framework have mortality windows of two to five years from diagnosis. The current model averages twelve to fifteen years from discovery to patient access. That gap is structural, not scientific. And it is a gap that kills.

The model in this work is not a reimagined process. It is a new one. Built from the patient backward. Every step exists only if it serves speed, safety, or efficacy. If it serves review, administration, or institutional protection, it gets compressed or removed. The patient is the record. The data travels. The clock starts at first symptom, not at first IND filing.

"Everyone wants to focus on a function. What they forget are the handoffs. And the fact that the continuity of data has to deliver end to end. It travels with the patient, not the health system, not the insurer, not the institution. The patient."

The economic model is not charity. A $966B annual burden on the US economy alone. A $262B global orphan drug market projected to exceed $500B by 2030. A development timeline where every year compressed represents life-years returned, cost-of-illness reduced, and earlier revenue entry for effective therapies. The case for this model is financial, clinical, and institutional simultaneously.

Quantum is included in this framework not as aspiration but as architecture. The Patient “Living” Record is only as trustworthy as its measurements. Quantum sensing does not drift. The cold chain verification required for a gene therapy at $2.1M per patient with no second dose requires a record that is physics-confirmed, not carrier-reported. The operating model does not wait for quantum. It runs without it. But it is designed so that when quantum reaches maturity at each contact point, it slots in as a verified upgrade to a system already running. Not a dependency. A planned acceleration.

Use the section navigation above to move through the full work: the five diseases, the bloat cited by phase, the new operating model, the system map, the economic case, the quantum hypothesis, and the sources.

Going to a quantum clinic should feel like going to your corner drugstore or your dry cleaner. Routine. Accessible. Something you do because it works. That is the bar. This framework is in active development. If you are working on rare disease drug development, patient registries, cold chain infrastructure, or quantum sensing applications in healthcare, the conversation is open.

Private and Confidential. Distribution requires prior written approval from 6SenseGlobal, LLC.

Five diseases. Five clocks no one should be forced to wait on.

Selected by mortality burden, pace of disease, diagnosis delay, and therapeutic inadequacy. Pulmonary fibrosis is included because it must be.

01
Idiopathic Pulmonary Fibrosis (IPF)
Diagnosis to death: 2–5 years. Median survival: 3 years.
~100K US patients 40K deaths/yr US Dx delay: 1–2 yrs

A crystallizing, irreversible fibrotic cascade. Only two approved treatments slow, not stop, decline. Lung transplant is the only curative option, viable for fewer than 5% of patients. The disease progresses while the system reviews.

Lancet (2024) · NCBi ILD Burden Study (2024) · PMC12206815
02
Amyotrophic Lateral Sclerosis (ALS)
Diagnosis to death: 2–5 years. Median: 3 years from symptom onset.
~30K US patients $47K+ first-year cost Dx delay: 9–12 months

Total motor neuron death. No curative therapy. Three approved drugs extend life by months. The clinical trial failure rate exceeds 95%. By the time most patients enroll in a trial, their disease has progressed beyond the study’s target population. The function-first system misses them entirely.

03
Duchenne Muscular Dystrophy (DMD)
Life expectancy: late 20s–30s. Diagnosis age: 2–5.
~15K US patients X-linked recessive Dx delay: avg 2.5 yrs

A child diagnosed today will likely spend their teenage years in a wheelchair and their twenties on ventilatory support. Gene therapy is in trial. Exon-skipping drugs are approved for subsets. Manufacturing complexity for personalized therapies creates supply fragility at exactly the moment patient populations are small and irreplaceable. The handoffs between research, manufacturing, and clinical care are where these patients fall.

04
Spinal Muscular Atrophy (SMA)
Type 1: death or ventilation by age 2 without treatment.
~10K US patients Most expensive drug: $2.1M Newborn screening: varies by state

SMA is the rare disease success story. Zolgensma and nusinersen have changed outcomes dramatically. But access, cold chain integrity, and the gap between approval and administration remain failure points. The therapy exists. The delivery system is what fails patients. That gap is a data continuity problem, not a science problem.

05
Cystic Fibrosis (CF)
Median survival: ~56 years (dramatically improved post-modulator era).
~35K US patients CFTR modulators: transformative Dx delay: historically 1+ yr

CF is the model for what is possible when science, community, and manufacturing align. CFTR modulators have transformed it from a progressive fatal disease into a manageable chronic condition. The lesson is not about the drug. It is about what happened when the data traveled with the patient across every function, every system, every border. The other four diseases need that same continuity. CF proves it is possible.

No company, CDM, CDMO, CRO, or specific therapy manufacturer is named in this framework. All statistics are drawn from cited public research.

Where the time goes. What it costs in lives.

Average rare disease drug development: 12–15 years from discovery to patient. Diagnosis delay: five years or more for most rare disease patients (2026). Of more than 10,000 identified rare conditions globally, fewer than 500 have an approved treatment. The time is not all necessary. Much of it is structural. And most of the structure exists to serve functions, not patients.

Bloat Phase 1: Discovery to IND
Pre-clinical and IND submission
Current: 3–6 years
Sequential review cycles. Animal studies designed for large-population assumptions, not rare disease pathophysiology. IND packages built on templates developed for blockbusters, inappropriate for ultra-rare populations of under 500 patients globally. Every function hands off to the next. No one owns the thread.
New Model: Discovery to IND
Parallel pre-clinical + regulatory engagement
Target: 18–24 months
FDA INTERACT meetings at day 30. Pre-IND living data package, continuously updated, not compiled at submission. Natural history data as regulatory evidence. Animal study waivers where biomarker-validated models exist and human organoid data is available.
Bloat Phase 2: Patient Identification
Diagnosis and trial enrollment
Current: 4.8-year avg diagnosis delay; enrollment: 12–36 months
Patients arrive at a rare disease diagnosis after years of misdiagnosis. No global patient registry that travels with them. Trials recruit from academic medical centers and miss community-diagnosed patients entirely. 85% of rare disease trials fail to enroll on time. The patient exists in the system as a file at each institution. Never as a continuous record.
New Model: Patient Identification
Living patient registry + pre-screened cohorts
Target: <6 months from first symptom
Universal newborn screening expansion. AI-assisted differential diagnosis at primary care. Living patient registry that follows the patient from diagnosis, not from trial enrollment. Patient is the record. Pre-consented cohorts reduce enrollment from months to weeks.
Bloat Phase 3: Clinical Evidence
Phase I–III trials
Current: 7–12 years, combined
Phase I, II, and III conducted sequentially. Placebo-controlled designs that are ethically untenable for diseases with 2-year mortality windows. Endpoints designed for large populations rather than validated rare disease biomarkers. 95% or more of rare disease trials fail. Each phase treats the patient as a new enrollment, not as a continuous data record from first symptom.
New Model: Clinical Evidence
Adaptive, platform trials with living endpoints
Target: 2–4 years
Platform trials that evaluate multiple interventions simultaneously against a shared control arm. Adaptive design: interim analyses that stop futile arms early and accelerate promising ones. Validated rare disease-specific biomarkers as primary endpoints. Real-world evidence from living patient records as confirmatory evidence post-approval.
Bloat Phase 4: Regulatory Review
NDA/BLA submission and review
Current: 12–18 months standard; 6 months priority
Static dossier compiled at submission. Sequential review: clinical, then statistical, then labeling, then manufacturing sign-off. Each domain touches the same patient data independently, with no shared thread across the review. Complete response letters restart the clock. Each review function touches the same patient data independently, with no shared thread. In 2025, FDA approved 46 new medicines through CDER — more than half with orphan designation, over 70% using an expedited pathway. The function improved. The continuity did not.
New Model: Regulatory Review
Rolling, living submission, continuous review
Target: 3–6 months
Rolling submission from Phase II. Living dossier, updated continuously as data accrues, not frozen at a single point in time. Parallel technical review streams running simultaneously, not sequentially. Conditional approval at earlier data thresholds with real-world confirmatory registry requirements. The record never closes.
Bloat Phase 5: Manufacturing + Cold Chain
Commercial manufacturing and distribution
Current: 18–36 months post-approval; cold chain verification: manual, operator-reported
Manufacturing scale-up begins after approval. No pre-approval commercial manufacturing authorization. Cold chain documentation is operator-generated, carrier records, not independent physics-verified condition records. For cell and gene therapies: patient-specific manufacture with no redundancy. The therapy leaves the manufacturing site and enters a system that no longer knows where it came from or what happened to it in transit.
New Model: Manufacturing + Cold Chain
Pre-approval commercial scale + verified cold chain
Target: Ready at approval. Condition verified end-to-end.
Pre-approval manufacturing authorization for rare disease therapies above Phase II. Commercial-scale manufacturing runs in parallel with Phase III. If the trial fails, inventory is destroyed. If approved, patients receive therapy on day one. Cold chain condition verified by continuous physics-based record, not carrier-reported. The record is what makes the administration defensible.

Source: Drug Development Timeline Challenges · EURORDIS Diagnosis Survey · ERGOMED Accelerating Rare Disease Development (2024)

Not a reimagined process. A new one.

The existing model was built for large populations, blockbuster economics, and sequential review. Not for a disease affecting 500 people globally. Not for a 3-year mortality window. Not for a therapy manufactured for a single patient.

Everyone wants to own a function. What they forget are the handoffs. The data has to travel through systems, processes, functions, and borders. With the patient. Not with the institution that treated them last. Not with the insurer that paid the last claim. With the patient.

Five principles: (1) The patient is the record — a living data model, not a submission package. (2) Parallel, not sequential — every workstream runs simultaneously. (3) The clock starts at first symptom, not at first IND. (4) The record never closes — approval is a checkpoint, not an endpoint. (5) Every step is measurable: time, cost, outcome, and life-years saved.

The five pillars of the new model

Pillar 01
The Patient “Living” Record

The patient is the anchor. From first symptom — not first diagnosis, not first enrollment — a continuous, physics-informed (sensors, cold chain, environmental condition), longitudinal data record follows the patient. Genomic, phenotypic, environmental, treatment response. Not compiled for a dossier. Never closed. Available to every authorized participant: the treating physician, the trial, the regulator, the payer. The record travels. The physician does not rebuild it from memory at every transition of care. The insurer does not dispute what the previous institution documented. The record is the thread.

Pillar 02
Parallel Orchestration

Pre-clinical, natural history, manufacturing process development, and regulatory engagement run in parallel, not in sequence. The IND is a checkpoint, not a gate. The NDA is a summary of continuous submission, not a document compiled on a deadline. No step waits for another step to close before beginning. The critical path collapses because there is no single critical path. There are parallel ones, all sharing the same underlying patient record.

Pillar 03
Platform Trial Infrastructure

A disease-specific platform trial — not a sponsor-specific one — evaluates multiple interventions against shared controls. The control arm is the living patient record. Interim analyses run continuously. Futile arms stop. Promising arms accelerate. Validated biomarkers replace mortality endpoints where a mortality-endpoint trial is ethically indefensible for a disease with a 3-year window. No patient waits 7 years for a result in a disease where 3 years is the median survival.

Pillar 04
Pre-Authorization Manufacturing

Commercial-scale manufacturing authorization begins at successful Phase II. Inventory is built in parallel with Phase III under a conditional manufacturing authorization. At approval, patients receive therapy within days, not 18 to 36 months later. For cell and gene therapies: redundant manufacturing nodes, not single-site dependency. The supply chain is validated before approval, not assembled after it. The handoff from manufacturing to distribution to administration is documented in the same record that began at the patient’s first symptom.

Pillar 05
Verified Cold Chain and Delivery Record

The condition of a therapy from manufacturing site to point of administration must be independently verified, not carrier-reported. For a gene therapy at $2.1M per patient with no second dose, the administration record must be defensible to every relying party: the payer, the regulator, the patient’s family. A cold chain record that was broken and undetected is not a cold chain record. It is a liability. That record is part of the patient’s continuous data thread. It does not live at the carrier. It travels with the dose.

This model does not name any company, sponsor, CMO, CDMO, or CRO. It is an operating architecture. The organizations that choose to build within it determine what gets built.

The new operating model, visualized

New nodes (the living record, parallel orchestration, platform trials) replace the sequential bottlenecks of the old model. Hover any node for context.

From Patient to Administration: New vs. Old
Old model: sequential gates, 12–15 years. New model: parallel orchestration with the Patient “Living” Record as the axis.
OLD MODEL: SEQUENTIAL (12–15 yrs) Discovery / Pre-clinical 3–6 yrs IND Submission ~1 yr Phase I / II Trials 2–4 yrs Phase III Trial 3–5 yrs NDA / BLA Review 12–18 mos Mfg Scale-up (post-approval) 18–36 mos Patient 12–15 yrs NEW MODEL: PARALLEL ORCHESTRATION (3–5 yrs) PATIENT “LIVING” RECORD the axis Discovery + Reg Parallel from Day 1 18–24 months Living Patient Registry Dx at first symptom · pre-consented <6 months diagnosis delay Pre-Auth Mfg Runs with Phase III Supply ready at approval Platform Trial Adaptive · multi-arm 2–4 years Rolling Submission Continuous · parallel review 3–6 months review Verified Cold Chain Physics-verified · sealed Independent record Patient 3–5 yrs Old model total: 12–15 years  ·  New model target: 3–5 years  ·  Time recovered: 7–10 years per therapy

Diagram is conceptual. Node interactions are illustrative of the new parallel architecture, not prescriptive sequence requirements.

Measurable for everyone at the table.

The new operating model is not a research proposal. It has an economic model, a productivity model, and a revenue model. These are the numbers that anchor it.

Current Burden
$966B
Estimated annual economic burden of rare diseases in the United States: direct medical costs, indirect costs, and productivity losses combined.
Development Cost
$2.6B
Average cost to develop and bring a single drug to market, including cost of failures. A figure rare disease economics cannot absorb without structural change.
Orphan Drug Market
$262B
Global orphan drug market size in 2024, projected to exceed $500B by 2030. The economic case for the new operating model is not charity; it is market capture.
Diagnosis Delay
5+ yrs
Time from first symptom to correct diagnosis for most rare disease patients, as of 2026. Each year of delay is a year of disease progression, care cost, and lost productivity that a continuous patient record would eliminate.
Time Compression
7–10 yrs
Estimated years recoverable under the new operating model per therapy: translating into life-years saved, reduced total cost of illness, and earlier market entry for effective therapies.
Model projection, based on ERGOMED Framework (2024)
ALS Year-1 Cost
$47K+
First-year care cost for a single ALS patient. A figure that continues through the disease course and after death through caregiver and family burden. Early diagnosis and faster therapy access changes this curve.

The three models

Economic Model
Cost per life-year saved vs. cost per year of delay
Measurable. Comparable. Fundable.
The economic model is built on a single metric: cost per quality-adjusted life-year recovered under the new operating model vs. the current one. Each year of development time compressed equals life-years returned to patients, reduced total cost of illness to payers, and earlier revenue entry for the sponsor. For a disease with $966B in annual US burden, compressing development time by 50% is not a research exercise. It is the single largest value-creation opportunity in healthcare. Federal research investment, commercial capital, and international development funding all share a common denominator: return on life saved per dollar invested. The new model makes that return calculable, comparable, and fundable. And because the data travels with the patient across borders and systems, the evidence base is global, not institution-specific.
Productivity Model
Parallel workstreams eliminate serial waiting time
Every parallel stream = months or years off the critical path.
The productivity model runs on a single principle: no step waits for another step to close before beginning. Pre-clinical and regulatory engagement: parallel. Phase II and manufacturing process development: parallel. Phase III and commercial manufacturing authorization: parallel. Rolling submission and Phase III completion: parallel. The model does not make each individual step faster. It eliminates the white space between them. That white space is where patients are lost, where data is re-entered at every handoff, where the same record gets rebuilt from scratch at each institution. The measure is time-to-enrollment, time-to-approval, time-to-patient, tracked against the living patient record as the baseline.
Revenue Model
Earlier market entry × defensible record × patient retention
The economics of rare disease require a new revenue logic.
Rare disease revenue does not follow blockbuster economics. Price per patient is high, patient population is small, and the value demonstration must be continuous, not static at approval. The revenue model has three components. First: earlier market entry. Each year of development compression is a year of exclusivity recovered. For an orphan drug at $500K per patient-year, one year of earlier entry on a 10,000-patient population is $5B in recovered revenue. Second: the defensible record. A living patient record and verified cold chain make the value case to payers continuously, not at a one-time HEOR submission. The data travels. It does not get rebuilt for each payer negotiation. Third: patient retention and evidence generation. A patient identified early, enrolled in a living registry, and treated with a verified product contributes real-world outcomes data that strengthens every subsequent reimbursement case. The patient is the revenue model’s most durable asset. That is not a phrase. It is the architecture.

Financial architecture: five diseases

The revenue model only holds if you model it accurately. For IPF, ALS, DMD, SMA, and CF, the financial mechanics below are structural realities that determine whether a therapy can be commercialized, priced, and sustained. They are not optional line items. Each dimension is disease-specific.

1. Gross-to-net waterfall: WAC is not collected revenue

IPF
Idiopathic Pulmonary Fibrosis

Nintedanib and pirfenidone are both Medicare Part D drugs. IRA inflation rebate penalties apply if WAC increases exceed CPI-U. The 2024 Part D redesign shifts catastrophic-phase liability to manufacturers (20%). PBM rebates and Medicaid Best Price set the floor. Net-to-gross discounts on established ILD therapies run 30–50% of WAC. A new entrant pricing above $80K/yr faces formulary exclusion without deep rebate concessions.

ALS
Amyotrophic Lateral Sclerosis

ALS faces the smallest US patient population (≈30K) and highest per-patient cost pressure. 340B hospital pricing applies at ALS specialty centers. Medicare is the dominant payer (median onset age 55–65). First-year direct care exceeds $47K before drug costs. IV-administered ALS therapies face additional hospital GTN mechanics via DRG assignment. Net revenue realization on a $150K–$200K WAC ALS drug is typically 55–65% after full GTN.

DMD
Duchenne Muscular Dystrophy

DMD is pediatric-onset — Medicaid is the dominant payer through childhood and adolescence. Medicaid Best Price is the binding floor. Exon-skipping drugs carry orphan designation: 7-year exclusivity plus a potential 6-month pediatric extension. 340B pricing at children’s hospitals further compresses net. For gene therapy entrants at $3M+ list, outcomes-based contracts with milestone repayment are becoming a payer prerequisite — model installment revenue recognition, not lump-sum at administration.

SMA
Spinal Muscular Atrophy

Zolgensma ($2.1M list) is the reference case for gene therapy GTN mechanics. Medicaid is the dominant payer for infants. CMS implemented outcomes-based contracts with installment payment structures. BPCIA biologics exclusivity (12 yr) and orphan drug exclusivity (7 yr) overlap — model the more protective, not both stacked. Nusinersen at $750K year-1 / $375K thereafter demonstrates how payer-mix shift from commercial to Medicaid compresses blended net realization over cohort life.

CF
Cystic Fibrosis

Trikafta/Kaftrio is the most commercially mature rare disease asset (WAC ≈$311K/yr). Net realization after PBM rebates, Medicaid Best Price, 340B, and Part D redesign is estimated at 55–65% of WAC. IRA small-molecule negotiation applies at 9 years post-approval (Trikafta approved 2019; MFP eligibility: 2028). CF is the model case for how GTN mechanics compound over product lifecycle as Medicare share grows with patient longevity improvement and as IRA MFP kicks in.

2. Tax credits, grants & non-dilutive capital

Orphan Drug Tax Credit (ODTC)
25% federal credit on qualified clinical testing expenses
All five diseases carry orphan drug designation. The ODTC applies to qualified clinical testing expenses — 25% federal credit. It reduces the deductible R&D expense dollar-for-dollar, so the net benefit is credit value minus lost deduction. For a clinical program spending $200M on qualified expenses: $50M ODTC credit, offset by ≈$42M in lost deduction at 21% — net benefit ≈$8M. Model it as a cash-flow line, not an accounting note. Applicable to all five: IPF, ALS, DMD, SMA, CF.
Section 174 Amortization
Mandatory capitalization: 5 yrs domestic, 15 yrs foreign
Post-2022, R&D expenses must be capitalized and amortized over 5 years (domestic) or 15 years (foreign). For a rare disease program spending $500M over 5 years, this creates a significant cash-tax timing mismatch: taxes paid during development even with no revenue. BARDA, NIH SBIR, and ARPA-H milestone grants partially offset this — model grant receipts as separate non-dilutive inflows. Critical for ALS, DMD, and SMA programs with large gene therapy development budgets.
ARPA-H / BARDA / NIH SBIR
Non-dilutive capital: disease-specific relevance
ARPA-H SURPASS (platform trial infrastructure for rare disease) is directly relevant to DMD, SMA, and ALS — diseases with platform trial feasibility and unmet need that meets ARPA-H mission criteria. BARDA relevance is highest for CF (pulmonary/infectious adjacency) and IPF. NIH SBIR Phase I/II grants are available for pre-commercial rare disease programs across all five designations. Model milestone-based inflows, not lump-sum. Each grant has specific IP, publication, and government rights provisions that affect commercial valuation. Non-dilutive capital can extend pre-IND and Phase I runway by 18–36 months without equity dilution.
Transferable & State-Level Credits
Massachusetts, Maryland, New Jersey: biotech-specific
Massachusetts Life Sciences Center incentives include transferable tax credits for qualifying life sciences investments. For pre-revenue rare disease companies with no tax liability to absorb credits, transferability is critical — a $5M credit sold at 85–90 cents on the dollar yields $4.25–4.5M in cash. Model transferable credits at market value, not face value. For DMD and SMA programs, pediatric rare disease designations may unlock additional state-level incentives. Map to jurisdiction of primary research operations — not all five diseases qualify in all states.

3. Regulatory exclusivity, IRA triggers & LOE erosion curves

Small Molecule (IPF, ALS, CF oral)
5 + 7 yrs
NCE exclusivity (5 yr) stacks with Orphan Drug (7 yr). Use the more protective. Add 6-month pediatric extension where applicable. LOE erosion: 70–90% revenue loss within 12–24 months of generic entry. Model as a step-function, not a linear decline.
Biologic / Gene Therapy (SMA, DMD)
12 + 7 yrs
BPCIA data exclusivity (12 yr) stacks with Orphan Drug (7 yr) — use the longer. Biosimilar/follow-on LOE erosion is more gradual: 20–40% over 3–5 years (payer inertia, cold chain complexity). Gene therapy assets with single-administration curative intent have no LOE analog — model competitive market share erosion instead.
IRA MFP Negotiation Trigger
9 / 13 yrs
Small molecules: MFP negotiation eligibility at 9 years post-approval (Medicare high-spend threshold). Biologics: 13 years. For ALS (new entrants), IPF (small molecule), and CF (Trikafta 2019 → MFP 2028): build the negotiation year and estimated MFP haircut (typically 25–60% below WAC) as a hard revenue cliff in the model.
Medicare Part D Redesign Liability
10 / 20%
Manufacturers pay 10% in the initial coverage phase and 20% in the catastrophic phase under the $2,000 OOP cap. For DMD and SMA gene therapies, this liability is single-episode but high-dollar. For ALS and IPF chronic oral therapies, it recurs annually per patient. Model as a separate cost line, not a GTN reduction.
Phase IV & PDUFA Commitments
$10–50M
Annual PDUFA program fees, NDA/BLA application fees, and mandatory Phase IV post-market surveillance for accelerated approvals (common in all five rare diseases). Confirmatory trials are a regulatory obligation for accelerated approval assets — failure to complete on time triggers potential withdrawal. Budget $10–50M in Phase IV commitments post-approval.
CPI-U Inflation Rebate Penalty
WAC cap
IRA mandates Medicaid rebate penalties when WAC increases exceed CPI-U inflation. Above CPI-U, the marginal revenue from a price increase goes to CMS, not to the sponsor. For IPF and ALS therapies with mature commercial assets, this is an active cash-flow constraint. Model WAC growth rate as a capped variable across the full commercialization horizon.

Model architecture checklist: by disease

Disease Dominant Payer Exclusivity Stack IRA Trigger LOE Erosion Key Credits / Grants
IPF Medicare (Part D) NCE 5yr + Orphan 7yr Yr 9 (small mol.) 70–90% / 12–24 mo ODTC, Sec. 174, BARDA
ALS Medicare (Part D/B) NCE 5yr + Orphan 7yr Yr 9 (small mol.) 70–90% / 12–24 mo ODTC, Sec. 174, ARPA-H
DMD Medicaid (pediatric) BPCIA 12yr + Orphan 7yr Yr 13 (biologic) 20–40% / 3–5 yrs ODTC, State credits, ARPA-H
SMA Medicaid (infant/child) BPCIA 12yr + Orphan 7yr Yr 13 (biologic) Market share erosion ODTC, Sec. 174, NIH SBIR
CF Commercial → Medicare NCE 5yr + Orphan 7yr Yr 9 (Trikafta → 2028) 70–90% / 12–24 mo ODTC, BARDA, state credits

Financial architecture reflects current US statutory and regulatory frameworks as of 2026. IRA MFP negotiations, PDUFA fee schedules, and state credit programs are subject to legislative change. No therapy-specific financial projections are made or implied. All figures are framework-level estimates for modeling architecture only. Distribution requires prior written approval from 6SenseGlobal, LLC.

Quantum as mechanism

Something is happening in physics labs, cold chain logistics nodes, and genomics research centers that most pharmaceutical organizations have not yet registered. It is not hype. It is not science fiction. It is early-stage, uneven, and in some places closer than the headlines suggest. The question is not whether quantum belongs in this model. The question is whether we have the architecture ready when it arrives.

The Operating Model First
Why architecture has to come before the technology
I want to be honest about something. We have been here before.

Every generation of technology that was going to transform drug development turned out to be only as good as the process it ran on. Genomics. AI. Real-world evidence platforms. Each one arrived with genuine promise, got layered onto a broken operating model, and produced a faster version of the same failure. The handoffs stayed broken. The data still did not travel with the patient. We got better tools inside a structure that was never designed to use them.

Quantum is next in that line. And the risk of repeating the same mistake is real.

Drug development today carries a clinical failure rate above 90% and an average cost above $2.6B per approved medicine, with timelines exceeding ten years from discovery to market. Frontiers in Drug Discovery, 2026 That failure rate is structural. It is not a hardware problem. No quantum processor, however powerful, fixes broken handoffs. No sensing technology, however precise, creates a record that was never designed to travel.

The operating model in this framework is the prerequisite. Build the architecture first. Define what the data must do. Where it must travel. What continuity means across systems, functions, and borders. Get that right, and quantum becomes an accelerant. Skip it, and quantum becomes the next expensive layer on a process still producing the same outcomes.
The Quantum Hypothesis
Two distinct problems, two distinct tools
When I look at where quantum physics actually intersects with the friction in this model, two problems stand out. Not quantum in general. Two specific, bounded problems that classical approaches genuinely cannot solve at the scale this architecture requires.

The first is verification. The Patient “Living” Record is only as trustworthy as its measurements. Classical sensors drift. They are tampered with. They produce records that are operator-reported, not physics-confirmed. That distinction matters enormously when a gene therapy costs $2.1 million per patient with no second dose and no reversal.

Quantum sensing does not drift in the same way. The measurement is the proof. As of January 2025, the NIHR had identified 63 quantum sensing technologies with active healthcare applications, 78% still at early readiness (TRL 1 to 5) but six already at TRL 9. NIHR, Quantum Sensing in Healthcare, Jan 2025 The physics to verify condition at every node of the cold chain already exists in deployable form. The architecture to use it is what has been missing.

The second is pattern recognition in sparse data. Rare disease genomic and phenotypic datasets are high-dimensional and very small. Classical machine learning was not built for this. Coupled-cluster computation hits a hard wall at roughly 20 to 30 atoms, unable to model the electron correlation that drives binding selectivity in rare disease targets. Frontiers in Drug Discovery, 2026 Quantum-enhanced methods operate differently on that kind of data. Earlier biomarker identification. Earlier patient identification. Earlier signal from the platform trial, in populations too small for classical models to work confidently.

Neither capability is production-ready today. Both are on a development curve that intersects with this model’s deployment horizon. That is the bet worth making.

“The operating model does not wait for quantum. It runs without it. But it is designed so that when quantum reaches maturity at each contact point, it slots in as a verified upgrade to a system already running. Not a dependency. A planned acceleration.”

Where quantum applies in the new model
Four contact points, one coherent system
1. The Patient “Living” Record. Think about what it would mean if every measurement in a patient’s record was not reported by an operator but confirmed by physics. Nitrogen-vacancy diamond quantum sensors and Q-BiC biocompatible spin chips are already in active development for cellular-level in-vitro and in-vivo sensing. Nature Reviews Physics, 2025 At the environmental layer, quantum sensors at cold chain nodes verify condition continuously, without relying on the carrier’s own reporting. The record stops being a document someone assembles. It becomes a continuous physical measurement that travels with the patient.

2. The Platform Trial. This is where I find the most hope. Rare disease populations are small. Sometimes 200 patients globally. Sometimes fewer. Classical models fail here, not because they are poorly designed, but because they were never built for data this sparse and this high-dimensional. Research published in 2025 and 2026 identifies rare disease genomics as one of the highest-potential near-term applications of quantum machine learning. npj Digital Medicine, 2026 Earlier biomarker signals. Earlier interim analysis. Earlier adaptive decisions in an arm that might represent fewer than 50 patients in the world.

3. Cold Chain Verification. Gene therapies do not tolerate temperature excursions. A single break in cold chain can destroy a dose that took years and millions to produce, and cannot be replaced for a patient whose window may have passed. Quantum random number generation using Hadamard and Toffoli gate circuits creates tamper-evident records that are cryptographically unbreachable by classical or quantum adversaries. Peer-to-Peer Networking and Applications, Springer, 2025 Combined with distributed ledger and IoT sensor networks, the cold chain record becomes physics-confirmed at every node.

4. Regulatory Data Provenance. A rolling, living submission to a regulator requires that every data point be traceable, verifiable, and timestamped in a way that cannot be retroactively altered. That is not a feature request. That is the condition of trust. Quantum-secured provenance closes that gap without adding process overhead, and regulatory submissions are specifically identified as a near-term application by the pharma quantum research community. Drug Discovery World, April 2025
What quantum cannot do yet
Being honest about where we are
I want to hold two things at the same time, because I think the field deserves that honesty.

Quantum computing for drug discovery is early. TRL 2 to 3 as of 2026. No NISQ-era workflow has solved a pharmaceutically relevant problem in a deployed industrial setting. The published demonstrations all use small-molecule toy systems, carefully chosen to show what is possible, not yet what is production-ready. Fault-tolerant systems capable of full rare disease genomic simulation are post-2030, most estimates suggest. Frontiers in Drug Discovery, 2026 That is not a dismissal. That is a timeline. And it is a timeline that intersects with where this operating model will be in four to six years if the work starts now.

Quantum sensing is a different story. Six of the 63 identified healthcare quantum sensing technologies were already at TRL 9 as of 2025. Regulatory pathways are forming: Chipiron’s low-field quantum MRI system is targeting FDA 510(k) clearance in April 2027. The UK National Quantum Strategy Mission 3 target is NHS-wide quantum sensing deployment by 2030. NIHR, 2025 Cold chain quantum sensing is not a future possibility. For some applications, it is an engineering integration problem.

Regulatory validation frameworks for quantum-verified data are estimated to lag hardware readiness by three to five years. QuanMed AI, 2026 That gap is real. And the way to close it is to have an operating model already running that generates evidence regulators can evaluate. You cannot negotiate a framework in the abstract. You need data from a real system.

AstraZeneca has publicly targeted quantum-accurate virtual screening by 2030. Google’s quantum chemistry roadmap targets simulation of 100+ active electrons by the same year. QuanMed AI, 2026 These are not aspirational statements from organizations known for aspirational statements. They are engineering commitments from organizations that have already made significant investments. The timeline is real. It is not today. But it is close enough that the architecture question has to be answered now.

The question worth sitting with: If a child is diagnosed today with a condition affecting fewer than 500 patients globally, and quantum sensing can verify every measurement in her record, and quantum computing can find the biomarker signal in a trial too small for classical models to read, what does the development timeline look like? Not as a prediction. As a design challenge. The operating model defines the architecture. Quantum defines what that architecture can eventually run at. The work of this framework is to make sure the structure is ready.

Private and Confidential. Distribution requires prior written approval from 6SenseGlobal, LLC.

Cited references

All statistics and claims in this framework are drawn from publicly available, peer-reviewed or institutional sources, updated through 2026 where available. No company, sponsor, CMO, CDMO, or CRO is cited or referenced.

Private and Confidential. Distribution requires prior written approval from 6SenseGlobal, LLC.